Misuse is
Int J Hematol (2001) 73(3):2717.10.1007/Bf02981951 100 SchaeferTSSandersLKNathansD
doi: 10.1016/S1043-2760(01)00524-0 72 Suczanowska-GabowskaSStaniszewskaMMarchlewiczMDuchnikEuczkowskaKSafranowKet al
By the same time, the FDA approved the use of a equimolar combination of IGF-1 and IGFBP-3 (Mecasermin Rinfabate, iPlex), suggesting that it would be a better choice, seeming as it will require lower doses because of the augmented half-life of the molecule and buffering effect on concentration
Trong qu trnh s dng thuc, ngi bnh cn tun theo hng dn ch nh ca bc s, khng t iu chnh liu dng thuc t c mong mun ca bn thn
this area attracts attention from researchers studying tissue support, recovery speed, performance output, and the broader repair response